Abu-Sbeih H, Tang T, Ali FS, et al. - A case series of individuals with hematologic malignancies who got chimeric antigen receptor T-cell (CART), in a clinical trial or as the standard of care, and consequently experienced gastrointestinal adverse events (GI-AEs) between 2012 and 2018 was reported in order to illustrate the incidence and clinical characteristics of GI-AEs noted following CART. In 15% of individuals treated with CART, the occurrence of CART-associated GI-AEs was noted. These signs were typically mild and self-limiting in nature, needing only symptomatic treatment. Notwithstanding, CART could, in rare cases, result in refractory colitis.